TP53 and cancer: These insights may lead to the development of innovative “Ca2+-signaling drugs” that could enhance Ca2+ fluxes in (a subset of) cancer, but not in healthy, cells, thereby killing or sensitizing these cancers, including resistant p53-deficient cancers, to treatments.